Russian State Medical University Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2011
NCT01446484
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Department of Neurology, Russian State Medical University

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Kidney Failure, Chronic (Phase 2)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Renal Insufficiency (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 8